ZEAL Zealand Pharma A/S

31.35
-3.15  -9%
Previous Close 34.5
Open 31.9
Price To Book 6.1
Market Cap 1,131,167,973
Shares 36,081,913
Volume 9,530
Short Ratio
Av. Daily Volume 11,464
Stock charts supplied by TradingView

NewsSee all news

  1. Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia

    Press Release – No. 04 / 2020 Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia The Dasiglucagon

  2. Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 137,236,000

    Company announcement – No. 09 / 2020 Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 137,236,000 A total of 741,816 new shares (the "New Ordinary

  3. Valeritas Receives Court Approval of Sale of Business to Zealand Pharma

    BRIDGEWATER, N.J., March 20, 2020 /PRNewswire/ -- Valeritas Holdings, Inc. (OTCPK: VLRXQ) ("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery

  4. Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019

    Company announcement – No. 03 / 2020 Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019 Copenhagen, March 11, 2020 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL)

  5. Zealand Pharma hosts conference call on March 12 at 4 pm CET (10 am EST) to present full year results for 2019

    Press Release – No. 02 / 2020 Zealand Pharma hosts conference call on March 12 at 4 pm CET (10 am EST) to present full year results for 2019 Copenhagen, February 26, 2020 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due in 2020.
Dasiglucagon
Congenital hyperinsulinism
Phase 3 data due 2021.
Glepaglutide
Short bowel syndrome
NDA filing announced March 31, 2020.
Dasiglucagon
Severe hypoglycemia in diabetes
Phase 3 trial to commence late-2020.
Dasiglucagon dual-hormone pump therapy
Type 1 Diabetes
Phase 3 commencement of enrolment announced May 7, 2019.
Glepaglutide - extension trial
Short bowel syndrome
Phase 2 trial to commence early 2020.
BI 456906
Obesity / diabetes
Phase 1b trial to commence early 2020.
ZP7570
Short bowel syndrome (SBS)
Phase 2 data released March 30, 2020.
Dasiglucagon
Post bariatric surgery hypoglycemia
Phase 3 second trial initiation announced December 4, 2019.
Dasiglucagon
Congenital hyperinsulinism

Latest News

  1. Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia

    Press Release – No. 04 / 2020 Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia The Dasiglucagon

  2. Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 137,236,000

    Company announcement – No. 09 / 2020 Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 137,236,000 A total of 741,816 new shares (the "New Ordinary

  3. Valeritas Receives Court Approval of Sale of Business to Zealand Pharma

    BRIDGEWATER, N.J., March 20, 2020 /PRNewswire/ -- Valeritas Holdings, Inc. (OTCPK: VLRXQ) ("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery

  4. Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019

    Company announcement – No. 03 / 2020 Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019 Copenhagen, March 11, 2020 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL)

  5. Zealand Pharma hosts conference call on March 12 at 4 pm CET (10 am EST) to present full year results for 2019

    Press Release – No. 02 / 2020 Zealand Pharma hosts conference call on March 12 at 4 pm CET (10 am EST) to present full year results for 2019 Copenhagen, February 26, 2020 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL)

  6. Zealand Pharma to attend 9th Annual SVB Leerink Global Healthcare Conference

    Press release – No. 01 / 2020 Zealand Pharma to attend 9th Annual SVB Leerink Global Healthcare Conference Copenhagen, February 20, 2020 – Chief Executive Officer Emmanuel Dulac and Chief Financial Officer Matt

  7. Rexgenero Appoints David Horn Solomon as Chairman

    Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia (CLI), today announces that Dr. David Horn Solomon has been appointed to

  8. Zealand Pharma announces bid to acquire Valeritas

    Company announcement – No. 01 / 2020 Zealand Pharma announces bid to acquire Valeritas Zealand Pharma (NASDAQ:ZEAL) has submitted a bid to acquire substantially all assets of Valeritas Holdings, Inc. (NASDAQ:VLRX), a

  9. Valeritas Announces Agreement for Zealand Pharma to Acquire Business and Retain Employees

    BRIDGEWATER, N.J., Feb. 9, 2020 /PRNewswire/ -- Valeritas Holdings, Inc. (NASDAQ:VLRX) ("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device,

  10. Zealand Pharma initiates second Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism

    Press Release – No. 21 / 2019 Zealand Pharma initiates second Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism                Congenital hyperinsulinism (CHI) is a rare pediatric disease

  11. Zealand Pharma completes Phase 3 clinical program for HypoPal® rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investment

    Company announcement – No. 38 / 2019 Zealand Pharma completes Phase 3 clinical program for HypoPal® rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million

  12. Bernadette Connaughton Appointed to Syneos Health Board of Directors

    MORRISVILLE, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial

  13. Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019

    Press Release – No. 20 / 2019 Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019 Copenhagen, October 28, 2019 – Zealand Pharma A/S ("Zealand")

  14. Zealand Pharma expands its peptide platform with acquisition of Encycle Therapeutics

    Company announcement – No. 37 / 2019 Zealand Pharma expands its peptide platform with acquisition of Encycle Therapeutics                The transaction strengthens the leadership of Zealand Pharma (NASDAQ:ZEAL) in

  15. Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia

    Company announcement – No. 35 / 2019 Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia Median time to recovery from low blood glucose

  16. Zealand Pharma completes subscription of new shares and registration of capital increase

    Company announcement – No. 33 / 2019 Zealand Pharma completes subscription of new shares and registration of capital increase Copenhagen, September 11, 2019 – With reference to the company announcement no. 30/2019

  17. Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 559.6 million

    Company announcement – No. 30 / 2019 A total of 3,975,000 new shares (the "New Shares") have been subscribed for with expected gross proceeds of approx. DKK 559.6 million The private placement and directed

  18. Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

    The dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim's pipeline portfolio in obesity and diabetes The Phase 2 trial for BI 456906 is expected to be initiated in late 2019 and will

  19. Zealand Pharma to attend Morgan Stanley 17th Annual Global Healthcare Conference

    Press release – No. 19 / 2019   Copenhagen, August 29, 2019 – Zealand Pharma Chief Executive Officer Emmanuel Dulac will attend the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in

  20. Zealand Pharma appoints Matthew Dallas as new Chief Financial Officer

    Company announcement – No. 27 / 2019   Copenhagen, August 28, 2019 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and

  21. Zealand Pharma relocates headquarters to accommodate growth

    Press Release – No. 18 / 2019 Copenhagen, August 27, 2019 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of